Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.

Authors :: Bashir, Babar
Sharma, Manish
Juric, Dejan
Papadopoulos, Kyriakos P.
Hamilton, Erika P.
Richardson, Debra L.
Shapiro, Geoffrey
Sahai, Vaibhav
Mettu, Niharika B.
Wainberg, Zev A.
Alese, Olatunji B.
Dragovich, Tomislav
Hodgson, Graeme
Henry, Susan
Hall, Terence
Paul, Sofia
Roth, David A.
Kelly, Michael
Abdul Malak, Tanya
Klimek, Virginia
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p3080-3080, 1p
Publication Year :: 2023

Full Text Access

Tools